Walter M. Stadler to Biomarkers
This is a "connection" page, showing publications Walter M. Stadler has written about Biomarkers.
Connection Strength
0.217
-
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
Score: 0.069
-
Prognosis and prediction in a Facebook world. Cancer. 2009 Dec 01; 115(23):5368-70.
Score: 0.054
-
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
Score: 0.031
-
Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. Clin Transl Sci. 2018 07; 11(4):420-427.
Score: 0.024
-
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc. 2011 Jul-Aug; 18(4):392-402.
Score: 0.015
-
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
Score: 0.012
-
Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer. 2007 Dec 15; 110(12):2604-13.
Score: 0.012